Cargando…

Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany

Pediatric inflammatory multisystem syndrome temporally associated with SARS Cov2 (PIMS-TS) is a newly encountered disease in children sharing clinical features with Kawasaki disease, toxic shock syndrome, or macrophage-activating syndrome. Pathogenically, it is associated with immune-mediated post-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wehl, Götz, Franke, Jörg, Frühwirth, Martin, Edlinger, Michael, Rauchenzauner, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073661/
https://www.ncbi.nlm.nih.gov/pubmed/33919536
http://dx.doi.org/10.3390/healthcare9040481
_version_ 1783684181270724608
author Wehl, Götz
Franke, Jörg
Frühwirth, Martin
Edlinger, Michael
Rauchenzauner, Markus
author_facet Wehl, Götz
Franke, Jörg
Frühwirth, Martin
Edlinger, Michael
Rauchenzauner, Markus
author_sort Wehl, Götz
collection PubMed
description Pediatric inflammatory multisystem syndrome temporally associated with SARS Cov2 (PIMS-TS) is a newly encountered disease in children sharing clinical features with Kawasaki disease, toxic shock syndrome, or macrophage-activating syndrome. Pathogenically, it is associated with immune-mediated post-infectious hyperinflammation leading to short-term myocardial injury with yet unknown long-term outcome. We herein present three cases of PIMS-TS treated in our institution with divided doses of immunoglobulins and high dose acetyl salicylic acid, according to existing Kawasaki disease guidelines. Due to greater weight in adolescents affected and concerns of rheological sequelae following possible hyperviscosity, doses of immunoglobulins were divided and given 24 h apart with good tolerability. All patients recovered rapidly with normalization of previously encountered cardiac manifestations. As diagnosis of PIMS-TS should be made promptly, timing of therapy is of paramount importance for a favorable outcome. To date, no randomized controlled trial data exist concerning treatment recommendations. 1.8% (95% CI: 1.7% to 2.0%) of all children and adolescents in the county district of Ostallgäu were tested positive for SARS CoV-2, incidence of PIMS-TS was 1.7% (95% CI: 0.9% to 3.1%) among SARS CoV-2 positive tested earlier. As the pandemic is still ongoing, rising numbers of PIMS-TS in children might be expected.
format Online
Article
Text
id pubmed-8073661
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80736612021-04-27 Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany Wehl, Götz Franke, Jörg Frühwirth, Martin Edlinger, Michael Rauchenzauner, Markus Healthcare (Basel) Case Report Pediatric inflammatory multisystem syndrome temporally associated with SARS Cov2 (PIMS-TS) is a newly encountered disease in children sharing clinical features with Kawasaki disease, toxic shock syndrome, or macrophage-activating syndrome. Pathogenically, it is associated with immune-mediated post-infectious hyperinflammation leading to short-term myocardial injury with yet unknown long-term outcome. We herein present three cases of PIMS-TS treated in our institution with divided doses of immunoglobulins and high dose acetyl salicylic acid, according to existing Kawasaki disease guidelines. Due to greater weight in adolescents affected and concerns of rheological sequelae following possible hyperviscosity, doses of immunoglobulins were divided and given 24 h apart with good tolerability. All patients recovered rapidly with normalization of previously encountered cardiac manifestations. As diagnosis of PIMS-TS should be made promptly, timing of therapy is of paramount importance for a favorable outcome. To date, no randomized controlled trial data exist concerning treatment recommendations. 1.8% (95% CI: 1.7% to 2.0%) of all children and adolescents in the county district of Ostallgäu were tested positive for SARS CoV-2, incidence of PIMS-TS was 1.7% (95% CI: 0.9% to 3.1%) among SARS CoV-2 positive tested earlier. As the pandemic is still ongoing, rising numbers of PIMS-TS in children might be expected. MDPI 2021-04-18 /pmc/articles/PMC8073661/ /pubmed/33919536 http://dx.doi.org/10.3390/healthcare9040481 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Wehl, Götz
Franke, Jörg
Frühwirth, Martin
Edlinger, Michael
Rauchenzauner, Markus
Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany
title Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany
title_full Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany
title_fullStr Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany
title_full_unstemmed Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany
title_short Successful Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with COVID-19 (PIMS-TS) with Split Doses of Immunoglobulin G and Estimation of PIMS-TS Incidence in a County District in Southern Germany
title_sort successful treatment of pediatric inflammatory multisystem syndrome temporally associated with covid-19 (pims-ts) with split doses of immunoglobulin g and estimation of pims-ts incidence in a county district in southern germany
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073661/
https://www.ncbi.nlm.nih.gov/pubmed/33919536
http://dx.doi.org/10.3390/healthcare9040481
work_keys_str_mv AT wehlgotz successfultreatmentofpediatricinflammatorymultisystemsyndrometemporallyassociatedwithcovid19pimstswithsplitdosesofimmunoglobulingandestimationofpimstsincidenceinacountydistrictinsoutherngermany
AT frankejorg successfultreatmentofpediatricinflammatorymultisystemsyndrometemporallyassociatedwithcovid19pimstswithsplitdosesofimmunoglobulingandestimationofpimstsincidenceinacountydistrictinsoutherngermany
AT fruhwirthmartin successfultreatmentofpediatricinflammatorymultisystemsyndrometemporallyassociatedwithcovid19pimstswithsplitdosesofimmunoglobulingandestimationofpimstsincidenceinacountydistrictinsoutherngermany
AT edlingermichael successfultreatmentofpediatricinflammatorymultisystemsyndrometemporallyassociatedwithcovid19pimstswithsplitdosesofimmunoglobulingandestimationofpimstsincidenceinacountydistrictinsoutherngermany
AT rauchenzaunermarkus successfultreatmentofpediatricinflammatorymultisystemsyndrometemporallyassociatedwithcovid19pimstswithsplitdosesofimmunoglobulingandestimationofpimstsincidenceinacountydistrictinsoutherngermany